Current disease status-Recurrent cancer - Page 13 of 19 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Is lymph node density a better predictor of cancer-specific survival than number of positive lymph nodes?

Is lymph node density a better predictor of cancer-specific survival than number of positive lymph nodes?

Posted by on Jun 17, 2014 in Prostate cancer | 0 comments

In a nutshell This study compared the predictive ability of lymph node density and the absolute number of positive lymph nodes in patients with prostate cancer and lymph node invasion.   Some background Radical prostatectomy is the surgical removal of the prostate gland in prostate cancer. Chemotherapy may be used following surgery to...

Read More

When hormone therapy fails, what happens next?

When hormone therapy fails, what happens next?

Posted by on Jun 16, 2014 in Breast cancer | 0 comments

In a nutshell This analysis compared previous research to determine the most effective treatment for hormone receptor positive breast cancer patients whose disease has progressed despite initial treatment.   Some background Hormone receptor positive breast cancer depends on the hormones estrogen or progesterone for growth. The principle...

Read More

Can removal of the primary tumor improve survival outcomes in stage IV colorectal cancer?

Can removal of the primary tumor improve survival outcomes in stage IV colorectal cancer?

Posted by on Jun 9, 2014 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to evaluate the impact of primary tumor removal and lymph node dissection on disease outcome in metastatic colorectal cancer.  Some background Approximately 15-20% of patients with colorectal cancer are diagnosed with distant metastasis (spread of the cancer) despite widespread screening. While in some...

Read More

Quality of life comparison for two prostate cancer treatments (proton therapy vs intensity modulated radiotherapy)

Quality of life comparison for two prostate cancer treatments (proton therapy vs intensity modulated radiotherapy)

Posted by on May 4, 2014 in Prostate cancer | 0 comments

In a nutshell This article examined quality of life of patients treated with proton therapy compared with intensity modulated radiotherapy (IMRT) among patients with localized (confined) prostate cancer.  Some background This article deals with two treatment choices for localized prostate cancer. The first is proton...

Read More

Emergency presentation: a risk factor for poor disease outcome in node-negative colorectal cancer

Emergency presentation: a risk factor for poor disease outcome in node-negative colorectal cancer

Posted by on Apr 29, 2014 in Colorectal cancer | 0 comments

In a nutshell This study examined the impact of emergency presentation on the outcomes of patients with node-negative colorectal cancer undergoing curative surgery. Some background Node-negative colorectal cancer is cancer that has not spread to the nearby lymph nodes. Curative surgery (surgical removal of all of the cancer cells)...

Read More

Selumetinib; a new MEK inhibitor tested

Selumetinib; a new MEK inhibitor tested

Posted by on Apr 28, 2014 in Melanoma | 0 comments

In a nutshell This phase II trial evaluated the efficacy and safety of selumetinib in combination with docetaxel (Taxotere) as first-line treatment for patients diagnosed with advanced melanoma. Some background Despite recent advances in targeted biological agents for the treatment of BRAF-mutated melanoma, treatment options for wild-type BRAF...

Read More

PD-1 inhibitors show promising early results

PD-1 inhibitors show promising early results

Posted by on Apr 26, 2014 in Lung cancer | 0 comments

In a nutshell This article reviews recent news regarding two new lung cancer drugs: nivolumab and MK-3475. Some background Nivolumab and MK-3475 are new drugs that belong to a class referred to as PD-1 inhibitors. PD-1 inhibitors work by blocking a specific protein (PD-1 or programmed cell death protein 1) found on many cells of the immune...

Read More

ACAT1 and prostate cancer progression

ACAT1 and prostate cancer progression

Posted by on Mar 30, 2014 in Prostate cancer | 0 comments

In a nutshell This study evaluated the efficacy of Acetyl-Coenzyme A acetyltransferase 1 (ACAT1) as a biomarker of prostate cancer progression. Some background Biomarkers or biological molecules used as clinical indicators have continued to impact prostate cancer management in terms of disease diagnosis and prognosis. Prostate cancer...

Read More